PRIMETEST II - Phase II Trial to Prospectively Test New Predictors for Recurrence in Patients With Clinical Stage II A/B Seminoma Treated With RA-RPLND

PRIMETEST II is an interventional study involving low-volume metastatic seminoma. It explores a novel approach using robot-assisted primary retroperitoneal lymph node dissection, aiming to reduce long-term side effects and improve quality of life. By identifying factors predicting cancer recurrence, the study hopes to tailor treatments for better outcomes. The approach could potentially spare patients from chemotherapy induced long-term side effects while maintaining excellent survival rates, presenting a promising shift in testicular cancer care for this specific patient group.

开始日期2023-08-28

申办/合作机构

Heinrich-Heine-Universität Düsseldorf

NCT05675410

/ Recruiting临床3期IIT

A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.

开始日期2023-05-11

申办/合作机构

National Cancer Institute

NCT03596918

/ CompletedN/AIIT

Longitudinal Quality of Life Study Among Participants With AIDS-Associated Kaposi Sarcoma at Bugando Medical Centre, in Mwanza, Tanzania

This pilot phase I trial studies how well treatment with vincristine and bleomycin affect quality of life in patients with acquired immunodeficiency syndrome (AIDS)-associated Kaposi sarcoma.

开始日期2018-10-10

申办/合作机构

University of California, Los Angeles

[+3]

100 项与硫酸博来霉素相关的临床结果

登录后查看更多信息

100 项与硫酸博来霉素相关的转化医学

登录后查看更多信息

100 项与硫酸博来霉素相关的专利（医药）

登录后查看更多信息

168

项与硫酸博来霉素相关的文献（医药）

2025-01-16·BLOOD

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma

Article

作者: Melear, Jason ; Feldman, Tatyana A. ; Burke, John M. ; Rana, Vishal ; Ho, Linda ; Friedman, Judah ; Gonzales, Paul ; Patel, Ameet ; Gandhi, Mitul D. ; Yimer, Habte ; Chintapatla, Rangaswamy ; Guo, Wenchuan ; Flinn, Ian W. ; Dean, Asad ; Yasenchak, Christopher A. ; Peterson, Matthew ; Linhares, Yuliya ; Lee, Hun Ju ; Raval, Mihir ; Metheny, Leland ; Islas-Ohlmayer, Miguel ; Ramchandren, Rod ; Renshaw, John ; Fanale, Michelle A.

Abstract:

Treatment options for stage I/II bulky and advanced-stage disease have recently extensively changed. For decades in North America, ABVD (doxorubicin hydrochloride [Adriamycin], bleomycin sulfate, vinblastine sulfate, and dacarbazine) has been a frontline standard-of-care option for patients with advanced classical Hodgkin lymphoma (cHL). Recent data on combining brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine demonstrated improved overall survival compared with ABVD but increased adverse events (AEs). We hypothesized that replacing vinblastine with nivolumab (brentuximab vedotin and nivolumab [AN] + doxorubicin and dacarbazine [AD]; AN+AD) may improve efficacy and safety. This phase 2, open-label multipart, multicenter study enrolled patients with treatment-naive stage II bulky or III/IV cHL. Patients received ≤6 cycles of AN+AD; granulocyte-colony stimulating factor (G-CSF) prophylaxis was optional, per institutional guidelines. At the time of planned analysis (N = 57), complete response (CR) and objective response rates were 88% (95% confidence interval [CI], 76.3-94.9) and 93% (95% CI, 83.0-98.1), respectively. With a median follow-up of 24.2 months (95% CI, 23.4-26.9), the 2-year progression-free survival rate was 88% (95% CI, 75.7-94.6); 88% (95% CI, 75.7-94.6) had a response lasting >2 years. Most common grade ≥3 treatment-related AEs were alanine aminotransferase increased (11%) and neutropenia (9%); 44% had treatment-related peripheral sensory neuropathy (grade 1/2, 40%; grade 3, 4%). No febrile neutropenia occurred; 49% received G-CSF prophylaxis. AN+AD led to a high CR rate and favorable safety profile. Further evaluation of programmed death receptor 1 inhibitor and CD30 antibody–drug conjugate combination regimens in frontline advanced-stage cHL is warranted. This trial was registered at www.clinicaltrials.gov as #NCT03646123 and www.clinicaltrialsregister.eu as #EudraCT 2020-004027-17.

2025-01-01·Hematology Transfusion and Cell Therapy

Lower doses of dacarbazine (modified BEACODD) as a safer strategy with equal effectiveness in an intensive treatment protocol of Hodgkin's lymphoma: a preliminary retrospective analysis of a single public center in Brazil

Article

作者: Dulley, Larissa Hilario ; Braga, Arthur Gomes Oliveira ; Rodrigues, Guilherme Garcia ; da Silveira, Talita Maira Bueno ; Chiattone, Carlos Sérgio ; Fortier, Sergio Costa

The German Hodgkin Study Group developed the escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) protocol as a treatment strategy for advanced-stage Hodgkin's lymphoma. In Brazil, as well as in other countries, procarbazine has been replaced with dacarbazine due to the limited availability of procarbazine. The Hematology Center at Irmandade da Santa Casa de Misericórdia in São Paulo adopted and modified the escalated BEACOPP protocol, substituting prednisone with dexamethasone and incorporating two different doses of dacarbazine: 375 mg/m²/day on Day 8 or the original dose of 250 mg/m²/day on Days 2 and 3. This adjustment was made in response to the anticipated toxicity profile. This study aimed to compare the two different doses in the protocols (375 mg/m²/cycle versus 500 mg/m²/cycle) administered to patients with advanced Hodgkin's lymphoma in similar periods. This retrospective study analyzed the data of 31 patients at a single center in Brazil from 2019 to 2021. Seventeen of the 31 patients received 500 mg/m²/cycle (500 Group), while 14 received 375 mg/m²/cycle (375 Group). At the end of the protocol, 71% of the patients in the 375 Group and 76% in the 500 Group achieved complete remission. On analyzing the number of cycles that patients presented with febrile neutropenia, the 500 Group had three times more events (17.9%) than the 375 Group (6.09% - p-value = 0.04). In the 500 Group, 47.1% needed to change the protocol to ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, and dacarbazine) due to toxicity. In this limited cohort from a single public center in Brazil, the use of 375 mg/m² of dacarbazine per cycle of the modified escalated BEACOPP protocol emerged as a safer strategy, maintaining treatment efficacy without compromising response in patients with advanced Hodgkin's lymphoma.

2024-12-01·Hematology Transfusion and Cell Therapy

Benefits of BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with advanced-stage Hodgkin's lymphoma: an analysis of the ECHELON 1 trial by the GATLA group using the Delphi Method

Article

作者: Altuve, Juan Ignacio Garcia ; Pavlovsky, Astrid ; Negri Aranguren, Florencia ; Aranguren, Flor Negri ; Cerutti, Amalia ; Warley, Fernando ; Fiad, Lorena ; Kurgansky, Nicolás

INTRODUCTION:

The BV-AVD (Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) combination for first-line treatment of advanced stage Hodgkin's lymphoma has been approved by regulatory authorities and included in international guidelines. However, several factors influence its incorporation as standard of care.

MATERIALS AND METHODS:

A group of experts from different institutions was identified and, using the Delphi method, an analysis of the results of the ECHELON 1 trial for the indication of BV-AVD over ABVD (doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine) in patients with Hodgkin's lymphoma Stages III and IV in Argentina was done. The clinical and academic experience of the authors and the context of the Argentine healthcare system were considered.

RESULTS AND DISCUSSION:

Seven statements on general aspects of the management of Hodgkin's lymphoma and nine on specific aspects related to the use of BV-AVD over ABVD reached a consensus of agreement. There was a strong expert consensus in favor of indicating BV-AVD in the presence of extranodal disease or pulmonary disease. Moderate to severe neuropathy, pregnancy and drug allergy were considered absolute contraindications to prescribe BV.

CONCLUSIONS:

The authors agreed that BV-AVD could be considered a new treatment option in high-risk patients. However health system-dependent factors (such as high cost, lack of availability, reimbursement difficulties, irregular delivery, and issues with granulocyte-colony stimulating factor availability) could pose limitations for this prescription. While awaiting new data from clinical trials and real-world studies, these recommendations can represent a useful tool for hematologists in different parts of the world.

项与硫酸博来霉素相关的新闻（医药）

2023-10-29

·Pharmaindustrial

Venus Remedies Granted Market Authorization for Bleomycin 15,000 IU in UK

Venus Remedies announce the achievement of market authorization in the United Kingdom for Bleomycin 15,000 IU Powder for Solution for Injection/Infusion by its German subsidiary, Venus Pharma GmbH. This remarkable milestone not only expands the pharma giant's global presence but also underscores its commitment to advancing cancer care with innovative solutions. Bleomycin 15,000 IU is a potent medication that contains the active ingredient bleomycin sulfate. It belongs to a group of medicines known as cytostatic drugs, specifically designed to combat cancer. This class of medications, often referred to as chemotherapy, is renowned for its effectiveness in targeting cancer cells and preventing their uncontrolled division. Its versatile applications include the treatment of certain types of squamous cell carcinomas in the head and neck, cervix, and external genitalia. It also serves as a panacea in treating severe types of lymph node cancers, such as Hodgkin's disease and non-Hodgkin's lymphoma of intermediate and high malignancy, testicular cancer, and fluid accumulation in the lungs, often associated with cancer. Bleomycin can be administered as a standalone treatment or in combination with other cancer medications and radiotherapy. Its effectiveness and utility in cancer treatment have earned it market authorizations in numerous countries worldwide. Venus Remedies is proud to hold a total of 15 Market Authorizations (MA) for Bleomycin products across the globe. As part of its efforts to make Bleomycin more accessible, the company has submitted sixteen additional applications to Ministries of Health (MOHs) around the world. Venus has secured 15 registrations for this drug across various regions, including Africa, Asia, the Middle East, the Commonwealth of Independent States (CIS), North America, and South America. "At Venus, our mission is to improve the lives of cancer patients by providing cutting-edge treatments. The UK's market authorization for Bleomycin 15,000 IU Powder for Solution for Injection/Infusion is a significant step towards realizing this mission. We remain dedicated to enhancing healthcare solutions and are committed to pursuing additional authorizations to reach even more patients in need," stated Saransh Chaudhary, CEO, Venus Medicine Research Center (VMRC). For Venus Pharma GmbH, the achievement of receiving market authorization from a regulatory agency like the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom is a significant validation of the company's commitment to pharmaceutical excellence. This achievement enhances the company's reputation, not only in the UK but also on the international stage, signifying its competence in delivering pharmaceutical products that can positively impact patient lives. Ashutosh Jain, CEO, Venus Pharma GmbH, expressed that obtaining market authorization from MHRA is a momentous accomplishment for Venus Pharma GmbH. It enables the company to play a pivotal role in advancing cancer care and improving the quality of life for patients facing this challenging disease.

上市批准

2022-04-21

·新浪医药新闻

李氏大药厂引进的抗肿瘤新药获批上市

4月21日，中国国家药监局（NMPA）官网公示，李氏大药厂子公司兆科药业申报的抗肿瘤新药盐酸丙卡巴肼胶囊（Natulan）上市申请已获得批准。根据李氏大药厂早前发布的新闻稿，该产品此次获批的上市申请针对的适应症为：用于治疗晚期霍奇金淋巴瘤。盐酸丙卡巴肼胶囊属于一种烷化剂药物，也是一种周期非特异性抗肿瘤药，在临床上适用于治疗晚期霍奇金淋巴瘤及部分脑癌（例如多形性胶质母细胞瘤）。据文献报道，该产品的抗肿瘤作用机制为：药物进入体内后经肝微粒体氧化代谢产生甲基或其他烷基自由基，再与DNA作用使其解聚，从而抑制DNA、RNA以及蛋白质的合成。公开资料显示，盐酸丙卡巴肼胶囊最初由罗氏（Roche）研发，已在海外获批上市，由Leadiant Biosciences（前身为Sigma-Tau公司）生产。李氏大药厂全资附属公司于2018年5月与Leadiant公司签署经销协议，以推进盐酸丙卡巴肼胶囊在大中华地区独家上市。 2020年5月，李氏大药厂发布新闻稿称，盐酸丙卡巴肼胶囊的新药上市申请已获NMPA受理。该申请基于一项开放、随机、受控及多中心的验证性研究结果（NCT02800447）。该试验由中国13个以上试验单位主导，旨在观察及比较BEACOPP基线方案组（包括博来霉素、依托泊苷、盐酸阿霉素、环磷酰胺、长春新碱、丙卡巴肼及泼尼松的联合化疗）及ABVD治疗方案组（包括盐酸阿霉素、博来霉素、长春碱及达喀尔巴嗪的联合化疗）对晚期霍奇金淋巴瘤患者的客观缓解率，并评估将盐酸丙卡巴肼胶囊用于治疗中国晚期霍奇金淋巴瘤患者的安全性。结果显示，该研究共有93名晚期霍奇金淋巴瘤患者参与研究，研究结果不仅与其主要最终目标匹配，即BEACOPP基线方案组的客观缓解率并不逊色于ABVD方案组。而且，在完成四个周期的治疗后，BEACOPP基线方案组（每个周期21天）的完全缓解率显著提高至16.22%（6/37），该数据在ABVD方案组（每个周期28天）则为2.17%（1/46）。霍奇金淋巴瘤是一种较为罕见的B细胞恶性淋巴瘤，多发生于20~40岁的年轻人，绝大部分患者病理分型为经典型霍奇金淋巴瘤。尽管早期霍奇金淋巴瘤治疗效果较好、治愈率较高，但许多患者由于治疗不规范、不良反应等原因，一线治疗后仍然会有较高的复发率。针对复发和难治性经典型霍奇金淋巴瘤，由于治疗方案少，肿瘤内科和血液科医生仍面临严峻的挑战。参考文献： [1] 2022年04月21日药品批准证明文件待领取信息发布. Retrieved Apr 21 , 2022. From https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20220421105823162.html [2] 喜讯集团治疗晚期霍奇金淋巴瘤的抗肿瘤药物——Natulan®新药上市申请已获NMPA受理，拟5月递呈优先审评申请. Retrieved May 21 , 2020. From https://mp.weixin.qq.com/s/ljJkVps-jhAhvny36ox4zA [3] 刘志军,陈河如.抗癌药物丙卡巴肼的合成工艺优化研究[J].中国药物化学杂志,2012,22(06):499-502.DOI:10.14142/j.cnki.cn21-1313/r.2012.06.011. 内容来源于网络，如有侵权，请联系删除，谢谢。

2022-02-22

·生物谷

经典霍奇金淋巴瘤(cHL)新药！CD30靶向药Adcetris(安适利)联合化疗：一线治疗显著延长生存期!

2022年02月22日讯--西雅图基因（Seagen）近日公布了3期ECHELON-1研究（NCT0112490）的数据，结果显示：接受抗体偶联药物（ADC）Adcetris（安适利，通用名：brentuximab vedotin，注射用维布妥昔单抗）联合化疗治疗的晚期经典霍奇金淋巴瘤（cHL）患者，总生存期（OS）有统计学意义的显著改善（p=0.009）。 ECHELON-1是一项随机、开放标签、国际性3期研究，在新诊断的晚期（III或IV期）cHL成人患者中开展，旨在比较Adcetris联合化疗方案AVD（阿霉素+长春新碱+达卡巴嗪）相对于目前公认的一线治疗NH的标准护理方案ABVD（阿霉素+博来霉素+长春新碱+达卡巴嗪）的疗效和安全性。该研究共入组了1334例经组织学确诊为III期或IV期cHL的成人患者，这些患者之前没有接受全身化疗或放疗。研究中，患者随机分成2个组，分别接受Adcetris+AVD方案（A+AVD）和ABVD方案治疗，最多6个周期。总生存期（OS）是该研究的关键次要终点。大约6年的中位随访结果显示：与ABVD方案组相比，A+AVD方案组死亡风险降低了41%（HR=0.59[95%CI:0.396-0.879]）。Adcetris的安全性与之前的研究一致，没有观察到新的安全信号。研究的详细数据将在即将召开的医学会议上公布。这些开创性的结果，对于晚期cHL患者非常重要。因为在一线治疗中，很少显示总生存期（OS）改善。 Adcetris已被批准用于某些类型的复发或难治性霍奇金淋巴瘤（HL），包括先前没有接受过治疗的晚期（III/IV期）cHL和之前没有接受过治疗的外周T细胞淋巴瘤（PTCL）。 Adcetris是一种抗体偶联药物（ADC），由靶向CD30蛋白的一种单克隆抗体和一种微管破坏剂（单甲基auristatin E，MMAE）通过一种蛋白酶敏感的交联剂偶联而成，该偶联技术为西雅图遗传学公司的专有技术。CD30蛋白是经典霍奇金淋巴瘤（HL）及系统性间变性大细胞淋巴瘤（sALCL）的明确标志物，而Auristatin E可通过抑制微管蛋白的聚合作用阻碍细胞分裂。Adcetris在血液中可稳定存在，在被CD30阳性肿瘤细胞内化后，可释放出MMAE。 Adcetris是治疗复发或难治性（r/r）cHL的标准护理药物，由西雅图遗传学公司研制，武田于2009年达成授权协议，获得了该药在除美国和加拿大之外全球其他国家的商业化权利。截至目前，Adcetris已获全球70多个国家批准，适应适应症多达6个，不同国家适应症有所不同。在美国，Adcetris已获批6个成人适应症，包括：（1）联合阿霉素+长春新碱+达卡巴嗪（AVD），一线治疗先前未接受过治疗（初治）的III期或IV期经典霍奇金淋巴瘤（cHL）；（2）接受自体造血干细胞移植（ASCT）巩固术后有升高的复发或进展风险的cHL；（3）接受自体HSCT治疗失败、或不适合自体HSCT且接受至少2种多药化疗方案失败的cHL；（4）联合环磷酰胺+阿霉素+强的松，一线治疗先前未接受过治疗（初治）的系统性间变性大细胞淋巴瘤（sALCL）或其他表达CD30的外周T细胞淋巴瘤（PTCL），包括血管免疫母细胞性T细胞淋巴瘤和未另行规定的PTCL；（5）先前接受过至少一种多药化疗方案治疗失败的sALCL；（6）先前已接受过系统治疗的原发性皮肤间变性大细胞淋巴瘤（pcALCL）或表达CD30的蕈样肉芽肿（MF）。在中国，国家药品监督管理局（NMPA）于2020年5月正式批准安适利（英文商品名：Adcetris，通用名：brentuximab vedotin，注射用维布妥昔单抗），用于治疗复发或难治性系统性间变性大细胞淋巴瘤（sALCL）或CD30阳性霍奇金淋巴瘤（HL）成人患者。目前，武田和西雅图遗传学公司正在积极推进一个大型的III期临床开发项目，目的是将Adcetris打造成一款治疗CD30阳性淋巴瘤的基础护理药物，并重新定义淋巴瘤的临床一线治疗。原文出处：ADCETRIS Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma 内容来源于网络，如有侵权，请联系删除，谢谢。

抗体抗体药物偶联物

100 项与硫酸博来霉素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02177	硫酸博来霉素	L01DC01	DBSALT000196

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
皮肤恶性肿瘤	日本	Nippon Chemical	1975-08-04
皮肤肿瘤	美国	Nippon Kayaku Co., Ltd.	1975-08-04
淋巴瘤	美国	Bristol Myers Squibb Co.	1973-07-31
恶性胸腔积液	美国	Bristol Myers Squibb Co.	1973-07-31
鳞状细胞癌	美国	Bristol Myers Squibb Co.	1973-07-31
睾丸肿瘤	美国	Bristol Myers Squibb Co.	1973-07-31

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
头颈部肿瘤	临床3期	美国	Inovio Pharmaceuticals, Inc.	2004-06-01
头颈部鳞状细胞癌	临床2期	法国	PCI Biotech AS	2012-04-01
头颈部鳞状细胞癌	临床2期	德国	PCI Biotech AS	2012-04-01
头颈部鳞状细胞癌	临床2期	立陶宛	PCI Biotech AS	2012-04-01
头颈部鳞状细胞癌	临床2期	荷兰	PCI Biotech AS	2012-04-01
头颈部鳞状细胞癌	临床2期	波兰	PCI Biotech AS	2012-04-01
头颈部鳞状细胞癌	临床2期	英国	PCI Biotech AS	2012-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02291133 (ECT-HCC, CTgov)	临床1/2期	原发性恶性肝肿瘤	25	Cliniporator Vitae®+Bleomycin PHC 15 e. (United States Pharmacopeia - USP)	範衊鑰餘壓鬱積膚夢鏇 = 襯構鑰範製築鹽鏇鹹齋選鹽鹽憲鬱積餘繭餘構 (壓鏇憲壓積餘齋鹽鬱製, 構夢顧鏇壓衊願範鬱衊 ~ 鬱鏇夢鬱鹽遞遞鏇窪餘) 更多	-	2021-07-23
NCT01132807 (CTgov)	临床2期	非霍奇金淋巴瘤	164	ABVD (Treatment (ABVD: 4 Cycles))	壓窪壓憲網願廠蓋遞顧 = 築鏇簾艱製淵鑰鑰鏇獵襯壓獵齋繭製襯鏇膚網 (構醖鏇繭選鏇選遞觸膚, 廠獵範顧鹽觸鏇觸獵衊 ~ 鑰鏇鏇齋壓觸淵憲鬱鑰) 更多	-	2021-06-14
				BEACOPP (Escalated BEACOPP and Involved Field Radiation Therapy)	憲鹽餘範簾築醖顧願遞 = 蓋蓋顧積製壓夢餘窪齋廠艱繭壓鬱繭糧夢獵淵 (繭獵範遞繭憲夢艱淵選, 淵繭窪繭獵淵築憲壓壓 ~ 網簾淵網鹹鏇構糧膚築) 更多
NCT00104676 (GETUG 13, CTgov)	临床3期	畸胎瘤 \| 非精原细胞生殖细胞肿瘤 \| 睾丸生殖细胞肿瘤	263	etoposide+cisplatin+bleomycin sulfate (Arm I)	繭膚鏇夢憲衊鬱簾鬱襯 = 鬱網鹽鹹繭壓膚醖蓋糧顧淵淵構觸壓願繭夢繭 (遞觸繭繭網廠觸襯膚製, 願鏇觸願鹽廠齋壓鏇範 ~ 膚醖構願齋顧獵鑰觸醖) 更多	-	2021-06-07
				etoposide+ifosfamide+paclitaxel+cisplatin+oxaliplatin+bleomycin sulfate (Arm II)	繭膚鏇夢憲衊鬱簾鬱襯 = 製鹽醖衊鑰鬱構艱鬱願顧淵淵構觸壓願繭夢繭 (遞觸繭繭網廠觸襯膚製, 廠選願膚壓鹽觸顧憲製 ~ 壓衊鹽艱鹹糧鹽膚膚製) 更多
NCT02352259 (CTgov)	临床2期	肝转移	23	Cliniporator Vitae®+Bleomycin PHC 15 e. (United States Pharmacopeia - USP)	艱餘積網網鑰壓膚襯衊 = 餘觸衊襯窪齋範壓構憲襯憲願廠鹽夢鏇壓鏇簾 (願觸鹽鏇餘窪齋製遞築, 襯觸衊鏇齋壓範築淵鬱 ~ 鬱鹹艱夢築網廠鑰鑰鬱) 更多	-	2021-03-24
NCT00025259 (AHOD0031, CTgov)	临床3期	霍奇金淋巴瘤 \| 小儿结节性硬化霍奇金淋巴瘤	1,734	Etoposide+cyclophosphamide+Prednisone+Filgrastim+Doxorubicin Hydrochloride+Vincristine Sulfate Liposome+Bleomycin Sulfate (Arm I (Patients Off-therapy Before Callback-Induction Only))	齋繭鹹廠艱餘壓艱繭製 = 糧夢衊窪願夢網壓鏇糧淵鹹廠構淵艱夢鑰衊壓 (艱夢網淵壓衊窪壓壓蓋, 構觸簾鹹艱鹽蓋鹹獵積 ~ 蓋願膚餘夢膚齋願鏇選) 更多	-	2017-03-07
				Involved-Field Radiation Therapy+Etoposide+cyclophosphamide+Prednisone+Filgrastim+Doxorubicin Hydrochloride+Vincristine Sulfate Liposome+Bleomycin Sulfate (Arm II (RER With CR [ABVE-PC, IFRT]))	齋繭鹹廠艱餘壓艱繭製 = 醖構鏇遞壓鹹齋觸壓鑰淵鹹廠構淵艱夢鑰衊壓 (艱夢網淵壓衊窪壓壓蓋, 鹹鹹衊鑰鹹齋積糧鑰壓 ~ 襯鏇簾觸構艱網艱淵顧) 更多